STOCK TITAN

Maze Therapeutics (MAZE) Stock Price, News & Analysis

MAZE NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
23 252 sessions, November 17, 2025 to November 17, 2026
Largest daily move
-35.2% close of March 25, 2026
1-year change
-2% closing prices, November 17, 2025 to November 17, 2026
1-month change
+19.4% closing prices, October 16, 2026 to November 17, 2026

Company Description

Maze Therapeutics, Inc. (Nasdaq: MAZE) is a clinical-stage biopharmaceutical company that focuses on developing small molecule precision medicines for patients with kidney and metabolic diseases, including obesity. According to the company’s public disclosures, Maze harnesses the power of human genetics to guide drug discovery and development, aiming to translate genetic insights into targeted therapies for clearly defined patient groups.

Maze is headquartered in South San Francisco, California and operates in the biotechnology industry within the healthcare sector. The company’s common stock is listed on The Nasdaq Stock Market under the ticker symbol MAZE, as noted in its SEC filings. Maze describes itself as a clinical-stage organization, meaning its lead drug candidates are in human clinical trials rather than commercial use.

Genetics-Driven Drug Discovery and the Compass Platform

Maze reports that its research and development engine is built around its proprietary Compass™ platform. The platform is designed to identify and characterize genetic variants associated with disease and then link those variants to the biological pathways that drive disease in specific patient groups. In its filings and press releases, Maze refers to this process as variant functionalization.

By integrating variant discovery with functional studies, Maze seeks to prioritize genetically validated targets for small molecule drug development. The company states that Compass is intended to inform multiple phases of the drug development process, including target selection and clinical trial design. Maze emphasizes that its goal is to use this genetics-based approach to discover and advance programs with first- or best-in-class potential in kidney and metabolic diseases.

Therapeutic Focus: Kidney and Metabolic Diseases

Across its public communications, Maze consistently describes its focus on kidney and metabolic diseases, including obesity and inherited metabolic disorders. The company highlights chronic kidney disease (CKD) and APOL1-mediated kidney disease (AMKD) as key areas of interest within nephrology, as well as phenylketonuria (PKU) within metabolic medicine.

Maze notes that AMKD is a subset of CKD that is estimated to affect over one million people in the United States alone. The company also references a broader CKD population that includes patients who inadequately respond to currently available therapies. In metabolic disease, Maze focuses on PKU, an inherited disorder characterized by elevated phenylalanine levels, and indicates that its approach is intended to be independent of specific genotypes or phenylalanine hydroxylase activity.

Lead Program: MZE829 for APOL1-Mediated Kidney Disease

Maze’s most advanced program, as described in its S-1 registration statement and press releases, is MZE829, an oral, small molecule inhibitor of apolipoprotein L1 (APOL1). MZE829 is being developed for patients with APOL1-mediated kidney disease (AMKD), which the company identifies as a genetically defined subset of CKD.

The company characterizes MZE829 as a dual-mechanism APOL1 inhibitor and notes that it is in Phase 2 clinical development. Maze is enrolling patients in the Phase 2 HORIZON trial, described as an open-label basket design study. According to Maze, this trial includes AMKD patients who carry two high-risk APOL1 alleles (G1 or G2) and covers a broad range of clinical phenotypes, including:

  • Patients with diabetic kidney disease
  • Patients with non-diabetic kidney disease, such as hypertensive nephropathy
  • Patients with severe focal segmental glomerulosclerosis (FSGS) and nephrotic-level proteinuria

Maze states that the HORIZON trial is intended to generate proof-of-concept data in this genetically defined population. Earlier Phase 1 data, as summarized in the S-1, indicated that MZE829 was evaluated in healthy volunteers across a range of doses, with Maze reporting that treatment was well tolerated at the doses tested and that pharmacokinetics were dose-proportional with relatively low variability.

Second Lead Program: MZE782 for PKU and Chronic Kidney Disease

The company’s second lead program is MZE782, described as an investigational, potent, oral inhibitor of SLC6A19, a sodium-dependent neutral amino acid transporter expressed in the small intestine and proximal tubule of the kidney. Maze is advancing MZE782 for two indications:

  • Phenylketonuria (PKU), an inherited metabolic disorder
  • Chronic kidney disease (CKD), including patients who may not respond adequately to existing CKD therapies

According to Maze, SLC6A19 plays a key role in the absorption and reabsorption of neutral amino acids, including phenylalanine (Phe). In PKU, SLC6A19 enables Phe uptake from the gut and reabsorption in the kidney, both of which contribute to elevated plasma Phe levels in patients with deficient phenylalanine hydroxylase activity. Maze explains that inhibiting SLC6A19 with MZE782 offers a genotype- and PAH-agnostic oral approach to lowering plasma Phe by limiting its entry into circulation.

In CKD, Maze states that SLC6A19-mediated reabsorption may contribute to metabolic overload in the kidney’s proximal tubule. By blocking this transporter, MZE782 may reduce the burden of amino acids and toxins, which Maze suggests could potentially slow disease progression. The company notes that this mechanism is complementary to, and distinct from, SGLT2 inhibition.

MZE782 has completed a Phase 1 randomized, double-blind, placebo-controlled study in healthy adult volunteers, as detailed in Maze’s press releases. Maze reports that MZE782 was well tolerated across all tested doses, with no serious adverse events observed. The company also reports dose-dependent increases in urinary excretion of phenylalanine and glutamine, which it interprets as evidence of target engagement and SLC6A19 inhibition. In addition, Maze notes that a dose-dependent initial dip in estimated glomerular filtration rate (eGFR) was observed, similar in magnitude to changes seen with certain renoprotective therapies, and that this effect reversed after dosing stopped.

Based on these findings, Maze has stated its intention to advance MZE782 into Phase 2 proof-of-concept trials in both PKU and CKD, with trial designs focusing on plasma Phe reduction in PKU and proteinuria reduction in CKD.

Broader Pipeline and Partnerships

Beyond its two lead programs, Maze references additional research and discovery efforts that also rely on its Compass platform. Public financial disclosures note prior license agreements, including an exclusive license with Shionogi & Co., Ltd. for rights to MZE001, an investigational oral glycogen synthase 1 (GYS1) inhibitor aimed at addressing Pompe disease by limiting disease-causing glycogen buildup. Maze has also disclosed an exclusive license agreement with Trace Neuroscience, Inc. for a discovery research program targeting UNC13A for the potential treatment of amyotrophic lateral sclerosis.

These collaborations illustrate that Maze’s genetics-guided approach has been applied to multiple therapeutic areas beyond its wholly owned kidney and metabolic programs, although the company’s current clinical focus, as described in its more recent communications, centers on MZE829 and MZE782.

Corporate and Capital Markets Profile

Maze Therapeutics is incorporated in Delaware, as indicated in its S-1 filing. The company identifies itself as an emerging growth company and a smaller reporting company under U.S. securities laws. Its common stock trades on The Nasdaq Global Market under the symbol MAZE.

In September 2025, Maze entered into a securities purchase agreement for an oversubscribed private placement of common stock and pre-funded warrants. The company’s press release and related Form 8-K state that the private placement was expected to generate gross proceeds of approximately $150 million, before fees and expenses. Maze has indicated that it intends to use these proceeds, together with existing cash, to advance MZE829 in AMKD, initiate Phase 2 trials of MZE782 in PKU and CKD, continue research programs, and further develop the Compass platform.

Maze subsequently filed a registration statement on Form S-1 to register the resale of shares issued in the private placement and shares underlying the pre-funded warrants. The S-1 describes the company’s business, risk factors, and clinical programs, and confirms that Maze’s common stock is listed on Nasdaq under the MAZE ticker.

Position Within Biotechnology and Therapeutic Areas

Within the biotechnology sector, Maze positions itself as a clinical-stage precision genetics company focused on kidney and metabolic diseases. Its public materials emphasize:

  • Use of human genetics to select and validate drug targets
  • Development of oral small molecule therapies rather than biologics
  • Concentration on renal indications such as AMKD and CKD
  • Expansion into metabolic and inherited disorders such as PKU and obesity-related conditions

Maze’s approach, as described in its filings and press releases, is to align therapeutic development with genetic evidence, aiming to match specific mechanisms—such as APOL1 inhibition or SLC6A19 inhibition—to well-defined patient populations.

Stock Performance

$31.81
-3.24%
-1.06
Last updated: at
-2%
Performance 1 year

Maze Therapeutics (MAZE) closed at $32.87 on November 17, 2026. Over the past 12 months, the price has lost 2.0%.

See what a $1,000 investment in MAZE would be worth today

Average down calculator for MAZE

MAZE Metrics & Rankings

Price returns through November 17, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Insider Radar

Net Sellers
90-Day Summary
0
Shares Bought
211,350
Shares Sold
30
Transactions
Most Recent Transaction
Coloma Jason V (Chief Executive Officer) sold 34,501 shares held indirectly at an average of $30.25 on November 2, 2026

Insider selling at Maze Therapeutics over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Maze Therapeutics reported operating income of -$142.9M in FY2025, and net income was -$131.1M. Diluted earnings per share stood at -$3.05. The company generated -$111.9M in operating cash flow. The current ratio was 15.50, measuring current assets divided by current liabilities.

-$131.1M
Net Income (FY2025)
-$111.9M
Operating Cash Flow
—
Revenue (FY2025)

Upcoming Events

DEC
01
December 1, 2026 Marketing

Evercore fireside chat

CEO Jason Coloma to join a fireside chat at the Evercore Healthcare Conference; live webcast archived for 60 days on investor site.
H1
2027
H1 2027 Clinical

HORIZON pivotal target

Maze targets initiation of a pivotal trial for MZE829 in APOL1-mediated kidney disease in H1 2027, subject to regulatory feedback.
YEAR
2027
2027 Clinical

CIPheR topline results

Topline results expected in 2027 from the Phase 2 CIPheR trial of MZE782 in phenylketonuria; timing and webcast details to be announced.
H1
2027
H1 2027 Clinical

MZE782 CKD trial

Phase 2 proof-of-concept trial of MZE782 in chronic kidney disease is planned for H1 2027; initiation and site details forthcoming.
H1
2027
H1 2027 Clinical

Pivotal trial planned

Planned pivotal trial for MZE829 in AMKD targeted for 1H 2027, advancement contingent on regulatory feedback and review.
YEAR
2027
2027 Clinical

MZE782 Phase 2 data

Initial Phase 2 data for MZE782 (SLC6A19 inhibitor) in phenylketonuria and CKD anticipated sometime in 2027.
YEAR
2027
2027 Clinical

Trial initiations 2027

Maze plans further trial initiations for MZE829 and MZE782 during 2027 to expand development programs and indications.
YEAR
2027
2027 Clinical

MZE829 final data

Final MZE829 Phase 2 HORIZON data expected in early 2027; topline timing subject to submission and webcast updates.
H1
2027
H1 2027 Clinical

Pivotal trial start

Maze plans a pivotal MZE829 trial in the first half of 2027, contingent on regulatory feedback and trial initiation notices.
YEAR
2027
2027 Clinical

CIPheR topline data

Topline data from the Phase 2 CIPheR trial of MZE782 for phenylketonuria expected sometime in 2027; investor updates to follow.

Maze Therapeutics has 10 upcoming scheduled events. The next event, "Evercore fireside chat", is scheduled for December 1, 2026 (in 13 days). Investors can track these dates to stay informed about potential catalysts that may affect the MAZE stock price.

Short Interest History

Last 12 Months

Short interest in Maze Therapeutics (MAZE) currently stands at 6.7 million shares, down 11.2% from the previous reporting period, representing 13.7% of the float. Since November 2025, short interest has increased by 201.0%.

Days to Cover History

Last 12 Months

Days to cover for Maze Therapeutics (MAZE) currently stands at 8.8 days, down 13.2% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 53.1%. Across the settlements charted above, it has ranged from 2.4 to 16.2 days.

MAZE Company Profile & Sector Positioning

Maze Therapeutics (MAZE) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing MAZE often look at related companies in the same sector, including Zenas BioPharma, Inc. (ZBIO), Zymeworks Inc. (ZYME), Nurix Therapeutics, Inc. (NRIX), Recursion Pharmaceuticals, Inc. (RXRX), and Trevi Therapeutics, Inc. (TRVI). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate MAZE's relative position within its industry.

Frequently Asked Questions

The current stock price of Maze Therapeutics (MAZE) is $31.81 as of November 18, 2026.

The market cap of Maze Therapeutics (MAZE) is approximately $1.7B. Learn more about what market capitalization means .

The FY2025 net income of Maze Therapeutics (MAZE) is -$131.1M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Maze Therapeutics (MAZE) is -$3.05 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Maze Therapeutics (MAZE) is -$111.9M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of Maze Therapeutics (MAZE), current assets divided by current liabilities, was 15.50 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Maze Therapeutics (MAZE) is -$142.9M for FY2025, its most recent completed fiscal year. Learn about operating income.

Maze Therapeutics focuses on developing small molecule precision medicines guided by human genetics for patients with kidney and metabolic diseases, including obesity. The company uses genetic insights to select and advance drug targets in these therapeutic areas.

Maze prioritizes kidney and metabolic diseases, with particular emphasis on chronic kidney disease, APOL1-mediated kidney disease, and phenylketonuria. The company also references obesity within its broader metabolic disease focus.

Maze’s lead programs are MZE829 and MZE782. MZE829 is an oral APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease. MZE782 is an oral SLC6A19 inhibitor advancing to Phase 2 with potential to treat phenylketonuria and chronic kidney disease.

The Compass platform is described by Maze as a genetics-based system that identifies and characterizes disease-associated genetic variants and links them to biological pathways. This process, which the company calls variant functionalization, is intended to guide target selection and inform clinical development of small molecule programs.

MZE829 is an oral, small molecule inhibitor of APOL1 being developed for patients with APOL1-mediated kidney disease, a genetically defined subset of chronic kidney disease. Maze is evaluating MZE829 in the Phase 2 HORIZON trial, which enrolls patients carrying two high-risk APOL1 alleles across a range of clinical phenotypes, including diabetic and non-diabetic kidney disease and severe focal segmental glomerulosclerosis.

SLC6A19 is a sodium-dependent neutral amino acid transporter expressed in the small intestine and kidney proximal tubule. Maze’s candidate MZE782 inhibits SLC6A19. The company reports that this mechanism is intended to lower phenylalanine levels in phenylketonuria and potentially reduce metabolic stress in chronic kidney disease by limiting amino acid reabsorption.

Maze has reported results from a Phase 1 randomized, double-blind, placebo-controlled trial of MZE782 in healthy adult volunteers. The company states that MZE782 was well tolerated across all doses and produced dose-dependent increases in urinary excretion of phenylalanine and glutamine, indicating target engagement and SLC6A19 inhibition, along with a reversible, dose-dependent initial dip in estimated glomerular filtration rate.

Maze Therapeutics is headquartered in South San Francisco, California, and is incorporated in Delaware, as disclosed in its SEC registration statements and filings.

Maze’s common stock is listed on The Nasdaq Stock Market, specifically The Nasdaq Global Market, under the ticker symbol MAZE, according to the company’s SEC filings.

In its S-1 registration statement, Maze identifies itself as an emerging growth company and a smaller reporting company under U.S. securities laws, which affects certain financial reporting and disclosure requirements.

Maze has stated that it intends to use proceeds from its 2025 private placement, together with existing cash, to advance MZE829 in APOL1-mediated kidney disease, initiate Phase 2 trials of MZE782 in phenylketonuria and chronic kidney disease, continue research and discovery programs, further develop its Compass platform, and support working capital and other general corporate purposes.